TMCnet News
Wound Management Technologies Appoints Ronald Goode and Jeffrey Lewis to the Board of Directors [Global Data Point](Global Data Point Via Acquire Media NewsEdge) Ronald Goode, Ph.D., has an extensive background in healthcare and brings a wealth of knowledge from a management and clinical perspective. Dr. Goode has served as President and CEO of Unimed Pharmaceuticals and eXegenics and held key management positions at Pfizer Pharmaceuticals and G.D. Searle %7E Co. He is currently the President and CEO of the Goode Group, a consulting firm advising Boards of Directors, senior executives and investment funds. Dr. Goode has also supervised clinical development programs for such blockbuster drugs as Pfizer's Procardia XL, Searle's Ambien and Unimed's Androgel. His experience extends globally where he presently serves on the Board of Directors of Hikma Pharmaceuticals. Under Sarbanes-Oxley, Dr. Goode is qualified to serve as an Audit Committee Financial Expert. He received his Ph.D. in Microbiology from the University of Georgia. "The opportunities that Wound Management Technologies have developing in the pipeline were extremely appealing when I took a seat on the board. With my background in healthcare, I look forward to guiding the company as it advances on its strategic growth initiatives. I am excited about the prospects of a company with a highly effective management team coupled with such an effective product as CellerateRX®," comments Dr. Goode. Jeffrey Lewis currently serves as President of the Institute for Healthcare Innovation. Mr. Lewis spent many years working in Congress and is the former President of the Heinz Family Philanthropies. He was an instrumental player in building healthcare solutions for both public and private employers. Having worked to manage the dramatic swell in healthcare costs, Mr. Lewis comments, "I am excited to join the board of a company like Wound Management Technologies that offers an economical solution to wound care that doesn't sacrifice the efficacy of the product. If we are to ever control the healthcare cost tsunami, we need practical solutions like CellerateRX®. The product represents a new market-based solution to manage wound care." (c) 2014 GlobalData Provided by SyndiGate Media Inc. (Syndigate.info). |